Condition: Esophageal Cancer · Surgery · Neoadjuvant Treatment · Sponsor: Henan Cancer Hospital
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant chemotherapy.
This description comes directly from the study's public registry record.
Yan Zheng, PhD, MD · +86+15713660065 · sunnyzheng1@126.com
Haibo Sun, PhD, MD · sunny-haipo@hotmail.com
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University) | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04280822